Tus%25252525252520qd

# Tus-QD ## Overview Tus-QD is a combination product typically containing **Hydrocodone Polistirex** (opioid antitussive) and **Chlorpheniramine Polistirex** (antihistamine) formulated as an extended-release suspension. The "QD" designation indicates the potential for once-daily dosing, though clinical practice often necessitates specific adherence to the FDA-approved labeling for the specific brand formulation. ## Primary Indications Relief of cough and symptoms associated with upper respiratory allergies or common colds in patients 6 years of age and older. ## Adult Dosing * **Standard Dose:** 10 mL (containing 10 mg hydrocodone and 8 mg chlorpheniramine) orally once every 12 hours (Note: Many proprietary "QD" formulations are labeled for every 12-hour dosing; verify if your specific product is physiologically extended for 24-hour delivery). * **Maximum Dose:** Do not exceed 20 mL in a 24-hour period. ## Pediatric Dosing * **Children 12 years and older:** 10 mL orally every 12 hours. * **Children 6 to 11 years:** 5 mL orally every 12 hours. * **Children under 6 years:** Not recommended due to lack of safety/efficacy data and risk of respiratory depression. ## Dose Adjustments * **Hepatic Impairment:** Consult product-specific labeling; generally, use with caution. Start at the lower end of the dosing range. * **Renal Impairment:** Use with caution. Hydrocodone metabolites may accumulate; consider increasing the dosing interval. * **Geriatric:** Initiate therapy at the lower end of the dosing range to minimize risks of sedation and falls. ## Contraindications * Hypersensitivity to hydrocodone, chlorpheniramine, or any component of the formulation. * Documented or suspected paralytic ileus. * Patients with significant respiratory depression or acute bronchial asthma (in settings without resuscitation equipment). * Use of MAO inhibitors within the last 14 days. ## Adverse Effects * **Common:** Somnolence, dizziness, nausea, vomiting, constipation, dry mouth. * **Serious:** Respiratory depression, urinary retention, hypotension, severe sedation, potential for abuse/misuse/addiction. ## Key Drug Interactions * **CNS Depressants:** Alcohol, benzodiazepines, and other opioids significantly increase the risk of profound sedation, respiratory depression, and death. * **MAOIs:** Risk of hypertensive crisis or severe serotonin syndrome. * **Anticholinergics:** Concurrent use increases risk of urinary retention, constipation, and confusion, particularly in the elderly. * **CYP450 Inhibitors/Inducers:** Hydrocodone is metabolized by CYP3A4 and CYP2D6; inhibitors may lead to toxicity, while inducers may reduce efficacy. ## Monitoring * **Respiratory Status:** Monitor for signs of slowed or shallow breathing. * **Sedation:** Assess for excessive somnolence. * **Constipation:** Monitor bowel regularity. * **Abuse Potential:** Screen for signs of OUD (Opioid Use Disorder). ## Clinical Pearls * **Shake well:** The polistirex formulation is a suspension; ensure adequate mixing before each dose to ensure accurate delivery. * **Measurement:** Always use a calibrated measuring device; household spoons lead to significant dosing errors. * **"QD" Confusion:** In clinical pharmacy, "QD" typically means once daily; however, many hydrocodone-chlorpheniramine extended-release suspensions are FDA-labeled for **BID (every 12 hour) dosing**. Always verify the specific manufacturer's label to ensure you are not under- or over-dosing based on the product name. * **Safety:** Provide counseling on the avoidance of alcohol and activities requiring mental alertness (driving/operating machinery). *** *Disclaimer: This information is for educational purposes only. Clinical protocols and product-specific labeling vary significantly. Always verify the current prescribing information via the FDA label or official drug compendia (e.g., Lexicomp, Micromedex) before prescribing or administering medication.*